Attomarker Launches Acceleration Round to Support Next Phase of Immunology Diagnostics Development
Exeter, United Kingdom – Attomarker, a leading UK-based diagnostics company, announced today the commencement of an Acceleration Round to support the next phase of commercial and clinical development of its innovative immunology diagnostics platform.
The company specializes in developing multiplex immune diagnostics that offer clinically relevant immune profiling from a single, small blood sample within minutes. These tests are designed for use in real clinical settings and are already being utilized by clinicians.
With a focus on immune profiling in patients with Long Covid, which is estimated to affect over 65 million people worldwide, Attomarker’s COVID Antibody Spectrum Test allows for immune classification of patients into one of three distinct endotypes. This supports treatment decision-making and monitoring of disease recovery, with two additional Long Covid companion tests currently in development.
In a recent strategic co-development agreement, Attomarker joined forces with EpitogenX to combine next-generation antigen technology with its diagnostics platform. This partnership aims to extend immune profiling into other immune-mediated conditions that are currently underserved by diagnostic options, with initial target areas including Lyme disease and Hashimoto’s disease.
The company holds a strong intellectual property position, with eight granted patents and a further patent pending, covering its core diagnostics technology and system architecture.
Currently, Attomarker’s diagnostics operate on a CE-marked benchtop device that is approved and in clinical use. A handheld device is also in development as an additional deployment option.
The Acceleration Round will support commercial rollout, regulatory progress, further clinical validation, and expansion of Attomarker’s immune profiling portfolio within Long Covid. Retail investor participation is being conducted through Crowdcube, a platform authorized and regulated by the Financial Conduct Authority. Non-retail investors can find more information on a separate information page on Attomarker’s website.
This announcement is provided for information purposes only and does not constitute an offer, solicitation, or invitation to invest.
Notes to Editors:
– Attomarker Launches Acceleration Round to support Next Phase of Immunology Diagnostics Development
– Exeter, United Kingdom
– February 8, 2026
– For more information about the Acceleration Round and investment opportunities, please visit: https://www.crowdcube.com/early-access/attomarker
– Non-retail investors can find more information here: https://attomarker.com/investors/
– This announcement is provided for information purposes only and does not constitute an offer, solicitation, or invitation to invest.
